Related Experiment Videos
The Nordic experience of cooperative urinary bladder cancer trials
P U Malmström1, E Rintala, S Hellsten
1Department of Urology, Uppsala University Hospital, Sweden.
Abstract:
The Nordic Urological Association Urothelial Group has been organizing phase 3 trials in urinary bladder cancer therapy since 1986. In total, around 1,000 patients from three countries have entered these studies. The results of the different trials are reviewed, and the problems with cooperative trials are discussed. The importance of these kind of trials in setting up management guidelines is underscored.
Insights
Since 1986, the Nordic Urological Association Urothelial Group has conducted phase 3 trials for urinary bladder cancer, involving approximately 1,000 patients. These cooperative trials are crucial for developing effective treatment guidelines.
Area of Science:
- Uro-oncology
- Clinical trial design
- Cancer therapeutics
Background:
- The Nordic Urological Association Urothelial Group initiated phase 3 trials for urinary bladder cancer therapy in 1986.
- These multi-national studies have enrolled approximately 1,000 patients across three countries.
Purpose of the Study:
- To review the outcomes of various phase 3 clinical trials in urinary bladder cancer.
- To discuss challenges encountered in conducting cooperative clinical trials.
- To emphasize the significance of these trials in establishing clinical management guidelines.
Main Methods:
- Review of results from multiple phase 3 clinical trials.
- Analysis of data from approximately 1,000 patients across three countries.
- Discussion of logistical and operational issues in cooperative research.
Main Results:
- Compilation and analysis of data from long-term phase 3 trials.
- Identification of common challenges in multi-center, international urothelial cancer research.
- Demonstration of the cumulative impact of cooperative trials on treatment standards.
Conclusions:
- Phase 3 trials organized by the Nordic Urological Association Urothelial Group have significantly contributed to urinary bladder cancer therapy.
- Cooperative trial methodologies present unique challenges but are vital for advancing cancer care.
- The findings underscore the essential role of collaborative research in shaping evidence-based guidelines for bladder cancer management.